Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
endTB-Q: New Regimens for Fluoroquinolone-Resistant MDR-TB
NCT03896685Phase 3Completed
- Sponsor
- Médecins Sans Frontières
- Start
- Apr 2020
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of bedaquiline and delamanid in Tuberculosis (TB) (2 arms), sponsored by Médecins Sans Frontières. Primary endpoint: Proportion of participants with favorable outcome at 73 weeks. Started Apr 2020; status: completed.
02
Drugs
bedaquilinedelamanid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT03896685.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03896685.